Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 7/20 | 0.33 |
| ▸ | MEN1 | O00255 | 6/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 4/20 | 0.33 |
| ▸ | NPC1 | O15118 | 3/20 | 0.33 |
| ▸ | RAB9A | P51151 | 3/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.32 |
| ▸ | PGR | P06401 | 2/20 | 0.31 |
| ▸ | LMNA | P02545 | 6/20 | 0.31 |
| ▸ | HPGD | P15428 | 2/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.31 |
| ▸ | MITF | O75030 | 1/20 | 0.31 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.31 |
| ▸ | ESRRG | P62508 | 1/20 | 0.31 |
| ▸ | HTT | P42858 | 2/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
| ▸ | USP2 | O75604 | 1/20 | 0.31 |
| ▸ | ATM | Q13315 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18220181 | 0.93 | SLC16A3 (0.33) | MAPTMEN1KMT2AALDH1A1MAPK1 | |
| SCHEMBL19293946 | 0.92 | MEN1 (0.32) | MAPTMEN1KMT2AALDH1A1MAPK1 | |
| SCHEMBL18220193 | 0.91 | ALDH1A1 (0.34) | MAPTMEN1KMT2AALDH1A1MAPK1 | |
| SCHEMBL25610046 | 0.89 | SLC16A3 (0.33) | MAPTMEN1KMT2AALDH1A1MAPK1 | |
| SCHEMBL18220222 | 0.85 | PGR (0.32) | MAPTMEN1KMT2AALDH1A1MAPK1 | |
| SCHEMBL24068151 | 0.85 | MEN1 (0.33) | MAPTMEN1KMT2AALDH1A1MAPK1 | |
| SCHEMBL18220185 | 0.85 | LMNA (0.47) | MAPTMEN1KMT2AALDH1A1MAPK1 | |
| SCHEMBL18221396 | 0.84 | PGR (0.31) | MAPTMEN1KMT2AALDH1A1MAPK1 | |
| SCHEMBL17120759 | 0.84 | MEN1 (0.37) | MAPTMEN1KMT2AALDH1A1MAPK1 | |
| SCHEMBL18220205 | 0.82 | KDM4E (0.32) | MAPTMEN1KMT2AALDH1A1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240208916-A1 | AMYLOID TARGETING AGENTS AND METHODS OF USING THE SAME | Amydis, Inc. | 2024-06-27 | — | — | US | disclosed |
| US-11718596-B2 | Amyloid targeting agents and methods of using the same | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2023-08-08 | — | — | US | disclosed |
| US-10934264-B2 | Amyloid targeting agents and methods of using the same | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2021-03-02 | — | — | US | disclosed |
| US-20200123118-A1 | AMYLOID TARGETING AGENTS AND METHODS OF USING THE SAME | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2020-04-23 | — | — | US | disclosed |
| US-10005745-B2 | Amyloid targeting agents and methods of using the same | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2018-06-26 | — | — | US | disclosed |
| US-20170248616-A1 | IN VITRO COMPOSITIONS COMPRISING HUMAN SAMPLE AND AMYLOID TARGETING AGENT | Amydis, Inc. | 2017-08-31 | — | — | US | disclosed |
| US-20160326126-A1 | AMYLOID TARGETING AGENTS AND METHODS OF USING THE SAME | Amydis, Inc. | 2016-11-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11718596-B2 | Amyloid targeting agents and methods of using the same | APP, CRYAA, APBA1 | MAPT 25/4885MEN1 2997/4885KMT2A 4649/4885 |
| US-20200123118-A1 | AMYLOID TARGETING AGENTS AND METHODS OF USING THE SAME | APP, CRYAA, APBA1 | MAPT 25/4885MEN1 2997/4885KMT2A 4649/4885 |
| US-20240208916-A1 | AMYLOID TARGETING AGENTS AND METHODS OF USING THE SAME | APP, CRYAA, APBA1 | MAPT 25/4885MEN1 2997/4885KMT2A 4649/4885 |
| US-20160326126-A1 | AMYLOID TARGETING AGENTS AND METHODS OF USING THE SAME | APP, APBA1, CRYAA | MAPT 26/4885MEN1 2973/4885KMT2A 4621/4885 |
| US-10934264-B2 | Amyloid targeting agents and methods of using the same | APP, CRYAA, APBA1 | MAPT 25/4885MEN1 2997/4885KMT2A 4649/4885 |
| US-10005745-B2 | Amyloid targeting agents and methods of using the same | APP, APBA1, CRYAA | MAPT 26/4885MEN1 2973/4885KMT2A 4621/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.